Muscle Pharm Corporation (MSLPQ)

[turokman]

-- Adjusted EBITDA was $2.4 million compared to negative Adjusted EBITDA of
$(11.6) million.

Ryan Drexler, President and Chief Executive Officer, stated, "Our management team has spent the last two years dramatically restructuring MusclePharm and are now generating positive cash flow and well positioned for long-term profitable growth even in the current COVID-19 pandemic environment. The business turnaround was driven by reducing low margin sales into inefficient channels, increasing gross margins, decreasing operating expenses and improving our overall EBITDA. We have many of the leading brands in nutrition but we needed to do a much better job of realizing the value of our brands by reducing product discounts and being more efficient in our promotional activity, reducing SKU's that are not properly positioned, and better aligning our operations with repositioned top-line growth.

Mr. Drexler continued, "We have strengthened our scalable platform in 2020, with a focus on increased profitability. Our omni-channel strategy is working and enables us to capture a greater share of this large and growing space. We also believe we are very well positioned to utilize our leading brands to expand outside of the nutraceutical space in the near future."